Loading
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, active and no longer recruiting.
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant is a phase 1 interventional study registered as NCT02477878 by Bellicum Pharmaceuticals, with 10 participants planned, started 2016-07. Conditions recorded: Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma and Hematologic Neoplasms. Interventions recorded: BPX-501 and Rimiducid.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/